How are BeOne Medicines (ONC) ADSs related to Ordinary Shares in this Form 4?

The Form 4 states that each American Depositary Share represents 13 Ordinary Shares of BeOne Medicines. This ratio links the ADSs traded in U.S. markets to the company’s underlying Ordinary Shares.

BeOne Medicines (ONC) SVP GC exercises options, sells 664 ADSs under 10b5-1 plan

Q: What insider transactions did BeOne Medicines (ONC) report for Lee Chan Henry?

BeOne Medicines reported that SVP and general counsel Lee Chan Henry exercised options to acquire ADSs and sold 664 ADSs on July 8, 2026 . The sale was executed in the open market under a Rule 10b5-1 trading plan .

Q: How many BeOne Medicines (ONC) ADSs did Lee Chan Henry sell and at what price?

Lee Chan Henry sold 664 American Depositary Shares of BeOne Medicines at $302.46 per ADS . The filing describes this as an open-market sale executed under a pre-arranged Rule 10b5-1 trading plan adopted in May 2026.

Q: What options did Lee Chan Henry exercise in the BeOne Medicines (ONC) Form 4?

The Form 4 shows option exercises covering 2,548 , 3,458 , and 2,626 Ordinary Shares at exercise prices of $12.23 , $16.41 , and $14.96 . These options relate to Ordinary Shares and have stated expiration dates between 2032 and 2034 .

Q: How many BeOne Medicines (ONC) Ordinary Shares does Lee Chan Henry hold after the transactions?

After the reported transactions, Lee Chan Henry held 338,884 Ordinary Shares of BeOne Medicines directly. This figure reflects his direct Ordinary Share holdings and is separate from his remaining option positions over additional Ordinary Shares.

Q: What does the Rule 10b5-1 trading plan note in the BeOne Medicines (ONC) filing mean?

The filing notes that the ADS sale was effected under a Rule 10b5-1 trading plan adopted on May 29, 2026 . Such plans pre-schedule trades, so the sale timing was determined in advance rather than being a discretionary, same-day trading decision.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BeOne Medicines Ltd. senior vice president and general counsel Lee Chan Henry reported option exercises and an associated sale of American Depositary Shares (ADSs). On July 8, 2026, he exercised options to acquire multiple blocks of ADSs and sold 664 ADSs at $302.46 per ADS in an open-market transaction pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he held 338,884 Ordinary Shares directly, and continued to hold several option positions over Ordinary Shares with stated exercise prices and future expiration dates.

Insider Trade Summary 10b5-1

Net Seller: 664 shares ($200,833)

Net Sell 8 txns

Insider Lee Chan Henry

Role SVP, General Counsel

Sold 664 shs ($201K)

Type	Security	Shares	Price	Value
Exercise	Share Option (Right to Buy)	2,626	$0.00	--
Exercise	Share Option (Right to Buy)	3,458	$0.00	--
Exercise	Share Option (Right to Buy)	2,548	$0.00	--
Exercise	American Depositary Shares	202	$194.47	$39K
Exercise	American Depositary Shares	266	$213.32	$57K
Exercise	American Depositary Shares	196	$159.03	$31K
Sale	American Depositary Shares	664	$302.46	$201K
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 17,238 shares (Direct, null); American Depositary Shares — 202 shares (Direct, null); Ordinary Shares — 338,884 shares (Direct, null)

Footnotes (1)

Each American Depositary Share represents 13 Ordinary Shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Key Figures

ADSs sold: 664 American Depositary Shares Sale price per ADS: $302.4600 per American Depositary Share Ordinary Shares held: 338,884 Ordinary Shares +4 more

7 metrics

ADSs sold 664 American Depositary Shares Open-market sale on July 8, 2026 by Lee Chan Henry

Sale price per ADS $302.4600 per American Depositary Share Price for 664 ADSs sold on July 8, 2026

Ordinary Shares held 338,884 Ordinary Shares Direct holdings after reported transactions

Option exercise block 1 2,548 Ordinary Shares at $12.2300 Share Option (Right to Buy) with expiration on June 4, 2034

Option exercise block 2 3,458 Ordinary Shares at $16.4100 Share Option (Right to Buy) with expiration on June 14, 2033

Option exercise block 3 2,626 Ordinary Shares at $14.9600 Share Option (Right to Buy) with expiration on August 4, 2032

ADS to Ordinary Share ratio 1 American Depositary Share to 13 Ordinary Shares Structure of BeOne Medicines’ ADS program

Key Terms

American Depositary Share, Rule 10b5-1 trading plan, Share Option (Right to Buy), Exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"The sale was effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

Ordinary Shares financial

"underlying_security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 04:44 PM Accepted by SEC EDGAR 07/10/2026 - 04:44 PM

FAQ

What insider transactions did BeOne Medicines (ONC) report for Lee Chan Henry?

BeOne Medicines reported that SVP and general counsel Lee Chan Henry exercised options to acquire ADSs and sold 664 ADSs on July 8, 2026. The sale was executed in the open market under a Rule 10b5-1 trading plan.

How many BeOne Medicines (ONC) ADSs did Lee Chan Henry sell and at what price?

Lee Chan Henry sold 664 American Depositary Shares of BeOne Medicines at $302.46 per ADS. The filing describes this as an open-market sale executed under a pre-arranged Rule 10b5-1 trading plan adopted in May 2026.

What options did Lee Chan Henry exercise in the BeOne Medicines (ONC) Form 4?

The Form 4 shows option exercises covering 2,548, 3,458, and 2,626 Ordinary Shares at exercise prices of $12.23, $16.41, and $14.96. These options relate to Ordinary Shares and have stated expiration dates between 2032 and 2034.

How many BeOne Medicines (ONC) Ordinary Shares does Lee Chan Henry hold after the transactions?

After the reported transactions, Lee Chan Henry held 338,884 Ordinary Shares of BeOne Medicines directly. This figure reflects his direct Ordinary Share holdings and is separate from his remaining option positions over additional Ordinary Shares.

What does the Rule 10b5-1 trading plan note in the BeOne Medicines (ONC) filing mean?

The filing notes that the ADS sale was effected under a Rule 10b5-1 trading plan adopted on May 29, 2026. Such plans pre-schedule trades, so the sale timing was determined in advance rather than being a discretionary, same-day trading decision.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Chan Henry

(Last)

(First)

(Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL

4051

(City)

(State)

(Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares								338,884	D
American Depositary Shares⁽¹⁾	07/08/2026		M		202	A	$194.47	202	D
American Depositary Shares⁽¹⁾	07/08/2026		M		266	A	$213.32	468	D
American Depositary Shares⁽¹⁾	07/08/2026		M		196	A	$159.03	664	D
American Depositary Shares⁽¹⁾	07/08/2026		S⁽²⁾		664	D	$302.46	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Share Option (Right to Buy)	$14.96⁽³⁾	07/08/2026		M			2,626	⁽⁴⁾	08/04/2032	Ordinary Shares	2,626	$0	17,238	D
Share Option (Right to Buy)	$16.41⁽³⁾	07/08/2026		M			3,458	⁽⁵⁾	06/14/2033	Ordinary Shares	3,458	$0	79,768	D
Share Option (Right to Buy)	$12.23⁽³⁾	07/08/2026		M			2,548	⁽⁶⁾	06/04/2034	Ordinary Shares	2,548	$0	105,300	D

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2026.

3. The number of securities underlying each option and the exercise price therefore are represented in ordinary shares.

4. These securities vest over a four-year period as follows: 25% on July 29, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

5. These securities vest over a four-year period as follows: 25% on the first anniversary of June 15, 2023 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 5, 2024 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

Exhibit List - Exhibit 24.1 - Power of Attorney

	/s/ Chan Henry Lee	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR